Micronutrient supplementation in maintenance haemodialysis patients enhances activity of antioxidant enzymes.

---Manuscript Draft---

<table>
<thead>
<tr>
<th>Manuscript Number:</th>
<th>JNEPHROL-D-11-00241R2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Title:</td>
<td>Micronutrient supplementation in maintenance haemodialysis patients enhances activity of antioxidant enzymes.</td>
</tr>
<tr>
<td>Short Title:</td>
<td>Micronutrient cocktail and oxidative stress.</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Original Articles</td>
</tr>
<tr>
<td>Section/Category:</td>
<td>Dialysis</td>
</tr>
<tr>
<td>Keywords:</td>
<td>Antioxidant enzymes; haemodialysis; micronutrient supplementation; oxidative stress.</td>
</tr>
<tr>
<td>Corresponding Author:</td>
<td>Peter John Garrett, MD</td>
</tr>
<tr>
<td></td>
<td>Western Trust</td>
</tr>
<tr>
<td></td>
<td>Omagh, N Ireland UNITED KINGDOM</td>
</tr>
<tr>
<td>Corresponding Author's Institution:</td>
<td>Western Trust</td>
</tr>
<tr>
<td>First Author:</td>
<td>Twyla Ann Moffitt, M Clin Res</td>
</tr>
<tr>
<td>First Author Secondary Information:</td>
<td></td>
</tr>
<tr>
<td>Order of Authors:</td>
<td>Twyla Ann Moffitt, M Clin Res</td>
</tr>
<tr>
<td></td>
<td>Peter John Garrett, MD</td>
</tr>
<tr>
<td></td>
<td>Mary Patricia Hannon-Fletcher, D Phil</td>
</tr>
<tr>
<td>Order of Authors Secondary Information:</td>
<td></td>
</tr>
<tr>
<td>Manuscript Region of Origin:</td>
<td>UNITED KINGDOM</td>
</tr>
</tbody>
</table>

**Abstract:**

**BACKGROUND**

Haemodialysis patients are exposed to high levels of oxidative stress, perhaps contributing to increased rates of cardiovascular and malignant disease. In this context the body’s defence mechanisms against oxidative insult, including activity of the antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx), are known to be deranged.

**METHODS**

This randomised double-blind study assessed the effects of a novel micronutrient cocktail containing physiological doses of antioxidant vitamins and trace minerals on antioxidant enzyme activity in maintenance haemodialysis. 37 patients were randomised to receive placebo or micronutrient. SOD and GPx activity was analysed at baseline and after six months of treatment.

**RESULTS**

SOD levels did not change in the treatment group but fell significantly ($p = 0.0443$) in controls, while activity of GPx remained unchanged in controls but rose significantly ($p = 0.0123$) in treated patients.

**CONCLUSIONS**

These results are consistent with a beneficial effect of the cocktail on antioxidant enzyme activity and may contribute to an indication for large scale studies to assess clinical outcome measures.

**Suggested Reviewers:**

Ian S Young, MD
Professor of Medicine, Queen’s University Belfast
| i.young@qub.ac.uk  
<table>
<thead>
<tr>
<th>Research interests in oxidative stress and vitamins.</th>
</tr>
</thead>
</table>
| A Peter Maxwell, MD  
| Professor of Nephrology, Queen’s University Belfast  
| peter.maxwell@belfasttrust.hscni.net  
| Research publications on antioxidant enzymes in dialysis. |

**Opposed Reviewers:**
Micronutrient supplementation in maintenance haemodialysis patients enhances activity of antioxidant enzymes.

SHORT TITLE
Micronutrient cocktail and oxidative stress.

AUTHORS
Twyla A Moffitt¹
Peter J Garrett¹
Mary P Hannon-Fletcher²

¹Western Renal Service, Tyrone County Hospital, Omagh and Altnagelvin Hospital, Derry/Londonderry

²Northern Ireland Centre for Food and Health, Biomedical Sciences Research Institute, University of Ulster, Coleraine
Northern Ireland, United Kingdom.
CORRESPONDING AUTHOR

Peter J Garrett MD
Renal Unit
Tyrone County Hospital
Hospital Road
Omagh
BT79 0AP
Northern Ireland
Telephone: +44 (0)28 82 833520
Fax: +44 (0)28 82 833563
peter.garrett@westerntrust.hscni.net

DISCLOSURES

The authors confirm that the manuscript has been seen and approved by all authors and that it is not under consideration for publication elsewhere in a similar form, in any language, except in abstract form.

This study was supported by an Amgen / Irish Nephrological Society Research Bursary.

No conflicts of interest to declare.
ABSTRACT

BACKGROUND

Haemodialysis patients are exposed to high levels of oxidative stress, perhaps contributing to increased rates of cardiovascular and malignant disease. In this context the body’s defence mechanisms against oxidative insult, including activity of the antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx), are known to be deranged.

METHODS

This randomised double-blind study assessed the effects of a novel micronutrient cocktail containing physiological doses of antioxidant vitamins and trace minerals on antioxidant enzyme activity in maintenance haemodialysis. 37 patients were randomised to receive placebo or micronutrient. SOD and GPx activity was analysed at baseline and after six months of treatment.

RESULTS

SOD levels did not change in the treatment group but fell significantly (p = 0.0443) in controls, while activity of GPx remained unchanged in controls but rose significantly (p = 0.0123) in treated patients.
CONCLUSIONS

These results are consistent with a beneficial effect of the cocktail on antioxidant enzyme activity and may contribute to an indication for large scale studies to assess clinical outcome measures.

KEYWORDS
Antioxidant enzymes; haemodialysis; micronutrient supplementation; oxidative stress.
INTRODUCTION

Haemodialysis patients have a much lower survival than the general population (1), with a huge excess cardiovascular mortality (2) and higher rates of cancer (3). Antioxidant status is disordered in chronic kidney disease (4) and haemodialysis itself promotes further oxidant insult (5). Markers of oxidative stress are higher in haemodialysis patients with as opposed to without cardiovascular disease (6), and perhaps oxidative damage to cellular macromolecules contributes to the amplified risk of cardiovascular and neoplastic disorders.

The organism’s defence against oxidative stress includes the antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx). Both these enzymes are known to be disordered in chronic kidney disease (7-10). Possible mechanisms include increased stimulation or exhaustion of enzyme systems by overwhelming oxidative challenge, altered expression of messenger RNA (11, 12), loss of renal functioning mass with reduction in synthetic capacity (13), and depletion of antioxidant vitamins or essential trace elements such as copper, zinc and selenium (8, 14) because of inadequate intake or excess removal by dialysis.

To investigate whether replenishment of physiological doses of trace elements and antioxidant vitamins could ameliorate this enzyme derangement, we studied the effects of a micronutrient cocktail (MNC) on SOD and GPx activity in maintenance haemodialysis patients.
SUBJECTS AND METHODS

The study received full ethical approval from the Office of Research Ethics Committees of Northern Ireland (ORECNI) and was conducted in adherence with the Declaration of Helsinki.

Adult subjects were recruited by interview, detailed information leaflet and signed informed consent from the haemodialysis populations programmes at Tyrone County Hospital, Omagh, and Altnagelvin Hospital, Derry/Londonderry, Northern Ireland. Exclusion criteria are shown in Table 1. 39 subjects in total were enrolled in the study.

All patients received thrice weekly haemodialysis against biocompatible membranes with the dialysis prescription adjusted to deliver a Kt/V of 1.2 or higher. All received erythropoiesis stimulating agents (epoetin alfa or darbepoetin alfa) to maintain haemoglobin according to Renal Association standards. Renal Association targets for calcium, phosphate and parathyroid hormone were maintained with phosphate binders and vitamin D analogues and, where required, cinacalcet according to NICE guidelines. Low dose parenteral iron was administered to maintain transferrin saturation >20%.

Subjects were randomised to receive a daily capsule containing the micronutritional cocktail (MNC) or placebo. The composition of the MNC is shown in Table 2 and is based on published recommended daily allowances in
the United Kingdom (15). Doses of water soluble vitamins were adjusted slightly to take account of losses during haemodialysis. The dose of folate was lower than these recommendations and based on published evidence of the quantity required to reduce plasma homocysteine levels (16). The dose of vitamin B12, on the other hand, was increased to avoid any risk of B12 deficiency neuropathy in the context of folate supplementation.

Concordance with medication was checked by monthly interviews and tablet counts. Clinical events were logged in the electronic patient record.

Clotted and whole blood samples (lithium heparin) were drawn predialysis at baseline, three months and six months. Serum and plasma were separated immediately and stored frozen at −70°C before analysis. SOD and GPx concentrations in red cells separated from lithium heparin samples were determined on the ILab650 analyser using commercially available kits from Randox Laboratories, Antrim, UK.

Group means were compared by paired or unpaired Student’s t-test as appropriate or, for non-normally distributed data, by the Wilcoxon rank sum test. Differences in proportions were tested by chi-square or Fisher’s exact test for parametric and non-parametric data respectively.
RESULTS

37 of the 39 subjects enrolled into the study were randomised. Serum phosphate was slightly lower in the placebo arm (1.25 versus 1.49 mmol/l, p = 0.0094), but baseline demographic, clinical, laboratory and therapeutic features, folic acid status and total antioxidant capacity as measured by the Ferric Reducing Ability of Plasma (FRAP) assay otherwise did not differ between the groups (Tables 3a and 3b). The placebo arm lost three subjects and the intervention arm four before completion. 30 subjects (14 in the intervention group and 16 in the placebo group) completed the study.

Baseline levels of SOD (1207 iu/gHb +/- 143.1 vs 1271 +/- 163.1; p = 0.7739) and GPx (79.82 +/- 10.65 vs 68.97 ± 5.934; p = 0.3655) (Figure 1) did not differ between the groups. Neither enzyme was influenced by age, gender, diabetes status, time since first dialysis, time since first renal presentation, or delivered dose of dialysis as Kt/V. Mean baseline SOD (1241) was close to the lower limit of the population reference range (1102 – 1601). Twelve of thirty subjects fell below the range.

SOD in control subjects showed a further significant fall six months after initiation of the study (1271 vs 880.9, p = 0.0443) (Figure 2). SOD in the intervention group, on the other hand, remained unchanged over the same period (1207 vs 1062, p = 0.3083). After six months, SOD levels in control subjects tended to be lower than in the treated group (880.9 vs 1062, p = 0.0688).
Baseline GPx, by contrast, tended to be higher (mean 74.03 iu/gHb) (Figure 3) than the population range (30-55), with 23 of 30 samples above the upper limit and only 7 lying within range.

GPx activity in the control group did not change during the study (68.97 vs 79.78, p = 0.1546) (Figure 4). In the intervention group, however, GPx rose significantly from a mean of 79.82 to 134.60 (p = 0.0123). After six months, GPx activity in the intervention group were highly significantly greater than in the control group (134.60 vs 79.78, p = 0.0001).
DISCUSSION

Antioxidant enzymes form a crucial part of the body’s defence against oxidative damage. Superoxide dismutase (SOD) is a suite of three enzymes responsible for catalyzing the dismutation of superoxide radicals into molecular oxygen and hydrogen peroxide. SOD3 is extracellular; the intracellular enzymes are soluble SOD1 in the cytoplasm and mitochondria, and mitochondrial SOD2. SOD1 is a homodimer binding copper and zinc and encoded by a gene at position 22.1 on the long arm of chromosome 21. SOD1 knockout mice display exaggerated age-related loss of muscle mass (17) and an increased frequency of hepatocellular carcinoma (18). The homotetramer SOD2, genetically encoded at locus 6q25, contains manganese; lack of this enzyme in mice is fatal within a few days of birth (19).

Glutathione peroxidise (GPx) is a family of eight enzymes acting downstream from SOD to reduce free hydrogen peroxide to water. The most abundant isoform is GPx1, a homotetramer containing selenium and encoded at 3p21.3. GPx1 knockout mice exhibit early development of cataracts (17).

Although there is considerable variation in reported results (20-26), our findings are consistent with many previous studies showing that SOD activity is reduced in renal failure (7-10, 27-29). This may reflect exhaustion of the enzyme system by exaggerated oxidant stress as well as low copper and zinc reserves (8) related to both dietary deficiency and increased losses across dialysis. The maintenance of SOD levels in our intervention subjects, in contrast to the placebo group, suggests a beneficial effect of the micronutrient supplement on the enzyme
system, either by replenishing exhausted trace metal reserves or by a general amelioration of oxidative stress.

By contrast, GPx activity in our subjects tended to be higher than in the general population. It may be that the GPx system had been upregulated in our patients to combat the increased levels of oxidative stress associated with uraemia and dialysis but, as a second line of defence, had not yet become exhausted. The significant increase in enzyme activity in the treated but not the placebo group once more supports a beneficial effect of the supplement.

Why however should GPx activity in our subjects be higher than in the general population, whereas levels in dialysis patients in most previous publications have tended to be low (5, 8, 10, 14, 24-28, 30, 31)? These papers include a study in Belfast (5) on a group of patients that, other than containing a higher proportion of urban dwellers, would have been constitutionally and environmentally very similar to our population.

The answer is almost certainly evident within the detailed description of the subjects in the Belfast study. These patients dialysed twice weekly against non-biocompatible cellulosic membranes. This was in an era before quality control of dialysis adequacy by Kt/V was commonplace and nutritional support for dialysis patients may also have been less advanced. In contrast, the patients in the current study were on at least thrice weekly dialysis against biocompatible membranes with careful monitoring of dialysis adequacy and regular specialist nutritional assessment. It is therefore likely that their exposure to oxidative stress, caused by both uraemia and by non-compatible dialysis membranes, was less than the Belfast cohort and probable that their nutritional reserves of trace
metals and anti-oxidant vitamins were greater. Thus the discrepancy in baseline GPx activity is entirely comprehensible.

We believe that the most likely explanation for the further increase in GPx activity after micronutrient supplementation represents an improvement in the ability of the enzyme system to combat continuing oxidative stress, possibly because of supplementation of nutrients essential for the system, including selenium. We consider the alternative hypothesis, that the enhanced activity (in the context of supplementation of antioxidant agents) reflects an increase in oxidative stress to be counterintuitive and, since SOD activity was maintained in the active but not in the placebo group, to be less likely. We have not as yet been able to measure selenium levels to provide support for this explanation.

Total antioxidant capacity by FRAP assay at the start of the study was identical between the active and control groups. We intend to derive additional information by measuring lipid peroxidation, but this has not yet been performed. We also plan to measure oxidative DNA damage using a modified COMET assay and will report these results separately.

The literature on controlled trials of the effects of dietary modification on oxidant stress in haemodialysis is limited. Supplementation with folic acid reduces homocysteine levels, in turn a risk factor for cardiovascular disease in haemodialysis patients, as well as improving plasma total antioxidant capacity (32). An open study of folate administration has claimed a beneficial effect (33), but results with vitamin B group supplementation have usually been disappointing: high doses of thiamine and pyridoxine did not ameliorate markers of oxidative stress (34) and folic acid alone (35) or with other B vitamins (36, 37) has not improved cardiovascular outcome (although the doses of folate used
were much higher than in the current study). Combination of folate and other B vitamins with vitamins E and C (38) has also failed to reduce markers of oxidative stress.

Administration of vitamin C alone to haemodialysis patients increases serum ascorbate levels (38) with potentially beneficial effects on malondialdehyde and lipid levels (40) and on plasma polypeptide characteristics (41). A randomized open-label trial did not however show any benefit on inflammation or oxidative stress (42). Intravenous ascorbate does seem to reduce intracellular production of reactive oxygen species (43) and has been combined with use of vitamin E coated dialysis membranes to enhance this effect (44).

Indeed, several small studies (45-47) have suggested benefit from vitamin E coated dialysis membranes on various markers of oxidative damage. A small randomised study (48) of oral supplementation with vitamin E confirmed changes in serum alfa- and gamma-tocopherol levels but was insufficiently powered to demonstrate amelioration of oxidative protein modifications. Another recent trial (49) has shown that both oral vitamin E and concentrated red grape juice (containing polyphenols) reduce levels of oxidised low density lipoprotein and neutrophil NADPH oxidase activity and that this effect is amplified by these agents in combination.

Although a further study of oral vitamin E has not shown any benefit on markers of microinflammation (50), a large controlled trial in haemodialysis patients with prevalent cardiovascular disease has demonstrated a reduction in composite cardiovascular endpoints and myocardial infarction (51). Similar results have been reported for antioxidant therapy with acetylcysteine (52).
In conclusion, although the data remain relatively scant, there is emerging evidence that anti-oxidant therapy may improve clinical outcomes as well as laboratory markers of oxidative stress. The effects of a combination of physiological doses of antioxidant vitamins and trace elements have not been described previously, and the potential of this simple intervention deserves further evaluation. This carefully controlled and blinded study has demonstrated clearly significant effects of a unique combined micronutritional supplement on activity of anti-oxidant enzymes. These results are consistent with an interpretation that the supplement supports enzyme systems in resisting oxidant stress and may provide support for further studies to determine whether this observation can be translated into clinical benefit for haemodialysis patients.
REFERENCES

1) Ansell D, Roderick P, Steenkamp R, Tomson CR.

2) Gurland HJ, Brunner FP, Dehn H, Harlen H, Parsons FM, Scharer K.

3) Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS.
   Increased incidence of malignancy during chronic renal failure.

4) Kuroda M, Asaka S, Tofuku Y, Takeda R.
   Serum antioxidant activity in uremic patients.
   Nephron. 1985; 41: 293-298.

5) Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER.
   Oxidative stress in haemodialysis.
   QJM. 1994; 87: 679-683.
6) Dirican M, Sarandol E, Serdar Z, Oacak N, Dilek K.
Oxidative status and prevalent cardiovascular disease in patients with chronic renal failure treated by hemodialysis.
Clin Nephrol. 2007; 68: 144-150

7) Shainkin-Kestenbaum R, Caruso C, Berlyne GM.
Reduced superoxide dismutase activity in erythrocytes of dialysis patients: a possible factor in the etiology of uremic anemia.
Nephron. 1990; 55: 251-253

Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure.
Nephron. 1991; 57: 10-15

9) Steiner M, von Appen K, Klinkmann H, Ernst B.
Superoxide dismutase activity and lipid peroxidation products in patients with chronic renal failure on maintenance haemodialysis.

10) Shurtz-Swirski R, Mashiach E, Kristal B, Shkolnik T, Shasha SM.
Antioxidant enzymes activity in polymorphonuclear leukocytes in chronic renal failure.

11) Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK.
Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency.
   mRNA study on Cu/Zn superoxide dismutase induction by hemodialysis
treatment.

13) Avissar N, Ornt DB, Yagil Y et al.
   Human kidney proximal tubules are the main source of plasma glutathione
   peroxidase.

14) Girelli D, Olivieri O, Stanzial AM et al.
   Low platelet glutathione peroxidase activity and serum selenium
   concentration in patients with chronic renal failure: relations to dialysis
   treatments, diet and cardiovascular complications.

15) Dietary reference values for food energy and nutrient intake for the United
    Kingdom. Report of the Panel on Dietary Reference Values of the Committee on

16) Variese AS, Verbeke F, Schrijvers BF, Lamiere NH. Is folate a promising
    agent in the prevention and treatment of cardiovascular disease in patients with


23) Senol E, Ersoy A, Erdinc S, Sarandol E, Yurtkuran M.
Oxidative stress and ferritin levels in haemodialysis patients.

24) Schettler V, Wieland E, Methe H, Schuff-Werner P, Müller GA.
Oxidative stress during dialysis: effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes.

25) Lim PS, Wei YH, Yu YL, Kho B.
Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy.

26) Mimić-Oka J, Simić T, Djukanović L, Reljić Z, Davicević Z.
Alteration in plasma antioxidant capacity in various degrees of chronic renal failure.

Antioxidant enzymes--superoxide dismutase and glutathione peroxidase--in haemodialyzed patients.
Carotid artery intima-media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis.

Erythropoiesis-stimulating agent withdrawal and oxidative stress in hemodialysis.

30) Roxborough HE, Mercer C, McMaster D, Maxwell AP, Young IS.
Plasma glutathione peroxidase activity is reduced in haemodialysis patients.

Haemolysis in haemodialysis patients: evidence for impaired defence mechanisms against oxidative stress.

32) Alvares Delfino VD, de Andrade Vianna AC, Mocelin AJ, Barbosa DS, Mise RA, Matsuo T.
Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients.
33) Righetti M, Serbelloni P, Milani S, Ferrario G.
Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.

Effect of high-dose thiamine and pyridoxine on advanced glycation end products and other oxidative stress markers in hemodialysis patients: a randomized placebo-controlled study.

35) Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP.
Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease.

B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial.

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
38) Kamgar M, Zaldivar F, Vaziri ND, Pahl MV.
Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease.

Oral vitamin C supplementation in hemodialysis patients and its effect on the plasma level of oxidized ascorbic acid and Cu/Zn superoxide dismutase, an oxidative stress marker.

Effect of vitamin C supplementation on oxidative stress and lipid profiles in hemodialysis patients.

Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment.
Proteomics 2006; 6: 993-1000.

Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients.
43) Tarng DC, Liu TY, Huang TP.
Protective effect of vitamin C on 8-hydroxy-2'-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients.

44) Yang CC, Hsu SP, Wu MS, Hsu SM, Chien CT.
Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress.

Vitamin E-coated dialyzer reduces oxidative stress in hemodialysis patients.

Vitamin E-bonded hemodialyzer improves neutrophil function and oxidative stress in patients with end-stage renal failure.

Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients.

48) Lu L, Erhard P, Salomon RG, Weiss MF.
Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial.
Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients.

Influence of oral vitamin E therapy on micro-inflammation and cardiovascular disease markers in chronic hemodialysis patients.


52) Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W.
The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial.
TABLES

TABLE 1

<table>
<thead>
<tr>
<th>Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt;18 years</td>
</tr>
<tr>
<td>Age &gt;80 years</td>
</tr>
<tr>
<td>On maintenance haemodialysis therapy for &lt;3 months</td>
</tr>
<tr>
<td>Smoking</td>
</tr>
<tr>
<td>Known alcohol abuse in previous 12 months</td>
</tr>
<tr>
<td>Severe liver disease</td>
</tr>
<tr>
<td>Severe uncontrolled cardiac or respiratory disease</td>
</tr>
<tr>
<td>Active neoplastic disease</td>
</tr>
<tr>
<td>Pregnancy</td>
</tr>
<tr>
<td>Breastfeeding</td>
</tr>
<tr>
<td>Participating in another clinical trial</td>
</tr>
<tr>
<td><strong>Supplement</strong></td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Vitamin C</td>
</tr>
<tr>
<td>Vitamin E</td>
</tr>
<tr>
<td>Vitamin K</td>
</tr>
<tr>
<td>Folic acid</td>
</tr>
<tr>
<td>Vitamin B2</td>
</tr>
<tr>
<td>Vitamin B6</td>
</tr>
<tr>
<td>Vitamin B12</td>
</tr>
<tr>
<td>Vitamin B5</td>
</tr>
<tr>
<td>Vitamin B1</td>
</tr>
<tr>
<td>Zinc</td>
</tr>
<tr>
<td>Copper</td>
</tr>
<tr>
<td>Selenium</td>
</tr>
</tbody>
</table>
TABLE 3a

BASELINE DEMOGRAPHIC AND CLINICAL FEATURES (PROPORTIONS)

<table>
<thead>
<tr>
<th>Feature</th>
<th>Active Group</th>
<th>Placebo Group</th>
<th>All</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>(%)</td>
<td>N</td>
<td>(%)</td>
</tr>
<tr>
<td>Male</td>
<td>10 (56)</td>
<td>12 (63)</td>
<td>22 (59)</td>
<td>0.7431</td>
</tr>
<tr>
<td>Female</td>
<td>8  (44)</td>
<td>7  (37)</td>
<td>15 (41)</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>7 (39)</td>
<td>6 (32)</td>
<td>13 (35)</td>
<td>0.7374</td>
</tr>
<tr>
<td>Renal Atherosclerosis</td>
<td>1 (6)</td>
<td>2 (11)</td>
<td>3 (8)</td>
<td>1.0000</td>
</tr>
<tr>
<td>Significant cardiac comorbidity</td>
<td>9 (50)</td>
<td>3 (16)</td>
<td>12 (32)</td>
<td>0.0750</td>
</tr>
<tr>
<td>Significant peripheral vascular comorbidity</td>
<td>2 (11)</td>
<td>3 (16)</td>
<td>5 (14)</td>
<td>1.0000</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>4 (22)</td>
<td>2 (11)</td>
<td>6 (16)</td>
<td>0.7140</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>3 (17)</td>
<td>1 (5)</td>
<td>4 (11)</td>
<td>0.4048</td>
</tr>
<tr>
<td>Inactive neoplastic disease</td>
<td>0 (0)</td>
<td>2 (11)</td>
<td>2 (5)</td>
<td>0.4865</td>
</tr>
<tr>
<td>All antihypertensive therapy</td>
<td>13 (72)</td>
<td>14 (74)</td>
<td>27 (73)</td>
<td>1.0000</td>
</tr>
<tr>
<td>ACEi or ARB therapy</td>
<td>8 (44)</td>
<td>7 (37)</td>
<td>15 (41)</td>
<td>0.7431</td>
</tr>
<tr>
<td>ESA therapy</td>
<td>18 (100)</td>
<td>19 (100)</td>
<td>37 (100)</td>
<td>1.0000</td>
</tr>
<tr>
<td>Parenteral iron therapy</td>
<td>12 (67)</td>
<td>17 (89)</td>
<td>29 (78)</td>
<td>0.1245</td>
</tr>
<tr>
<td>Phosphate binders</td>
<td>14 (78)</td>
<td>10 (53)</td>
<td>24 (65)</td>
<td>0.1704</td>
</tr>
<tr>
<td>Vitamin D analogues</td>
<td>15 (83)</td>
<td>10 (53)</td>
<td>25 (68)</td>
<td>0.0789</td>
</tr>
<tr>
<td>Cinacalcet therapy</td>
<td>2 (11)</td>
<td>0 (0)</td>
<td>2 (5)</td>
<td>0.4872</td>
</tr>
<tr>
<td>Statin therapy</td>
<td>11 (61)</td>
<td>12 (63)</td>
<td>23 (62)</td>
<td>1.0000</td>
</tr>
</tbody>
</table>

*Fisher’s exact test

** including diabetic nephropathy as primary renal diagnosis.

*as primary renal diagnosis.

active angina, previous myocardial infarction, previous coronary intervention, episode of heart failure requiring hospital admission.

active intermittent claudication, ischaemic rest pain, ischaemic ulcers, previous radiological or surgical intervention.
### TABLE 3b

**BASELINE DEMOGRAPHIC AND CLINICAL FEATURES (MEANS)**

<table>
<thead>
<tr>
<th>Feature</th>
<th>Active Group</th>
<th>Placebo Group</th>
<th>All</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td></td>
</tr>
<tr>
<td><strong>Age in Years</strong></td>
<td>64.50 (8.327)</td>
<td>63.25 (9.199)</td>
<td>63.83 (10.14)</td>
<td>0.7173</td>
</tr>
<tr>
<td><strong>Body Mass Index</strong></td>
<td>26.91 (5.219)</td>
<td>26.26 (4.978)</td>
<td>26.56 (4.909)</td>
<td>0.7301</td>
</tr>
<tr>
<td><strong>Time on Renal Replacement Therapy (months)</strong></td>
<td>27.45 (38.86)</td>
<td>32.24 (60.08)</td>
<td>29.84 (76.87)</td>
<td><strong>0.8156</strong></td>
</tr>
<tr>
<td><strong>Equivalent ESA dosage (units per week)</strong></td>
<td>6444 (3240)</td>
<td>6000 (2560)</td>
<td>6216 (2878)</td>
<td>0.6453</td>
</tr>
<tr>
<td><strong>Urea Reduction Ratio</strong></td>
<td>0.7378 (0.05231)</td>
<td>0.7363 (0.05737)</td>
<td>0.7370 (0.05420)</td>
<td>0.9360</td>
</tr>
<tr>
<td><strong>CRP</strong></td>
<td>10.39 (9.51)</td>
<td>13.58 (10.19)</td>
<td>12.03 (9.86)</td>
<td>0.3323</td>
</tr>
<tr>
<td><strong>Total calcium (mmol/l)</strong></td>
<td>2.351 (0.1288)</td>
<td>2.361 (0.1398)</td>
<td>2.356 (0.1328)</td>
<td>0.8328</td>
</tr>
<tr>
<td><strong>Serum albumin (g/l)</strong></td>
<td>34.06 (3.096)</td>
<td>35.16 (4.045)</td>
<td>34.62 (3.608)</td>
<td>0.3603</td>
</tr>
<tr>
<td><strong>Phosphate (mmol/l)</strong></td>
<td>1.492 (0.2188)</td>
<td>1.247 (0.3132)</td>
<td>1.366 (0.2952)</td>
<td>0.0094</td>
</tr>
<tr>
<td><strong>Alkaline phosphatase</strong></td>
<td>112.8 (102.3)</td>
<td>94.42 (29.42)</td>
<td>103.4 (73.93)</td>
<td><strong>0.4712</strong></td>
</tr>
<tr>
<td><strong>PTH</strong></td>
<td>241.6 (115.1)</td>
<td>185.1 (187.5)</td>
<td>212.6 (157.0)</td>
<td><strong>0.2750</strong></td>
</tr>
<tr>
<td><strong>Haemoglobin (g/dl)</strong></td>
<td>11.71 (1.461)</td>
<td>11.57 (0.9351)</td>
<td>11.64 (1.204)</td>
<td>0.7344</td>
</tr>
<tr>
<td><strong>Ferritin</strong></td>
<td>621.2 (363.7)</td>
<td>606.2 (342.0)</td>
<td>613.7 (348.0)</td>
<td>0.8993</td>
</tr>
<tr>
<td><strong>Transferrin saturation (%)</strong></td>
<td>28.50 (9.476)</td>
<td>30.11 (10.69)</td>
<td>29.31 (9.991)</td>
<td>0.6354</td>
</tr>
<tr>
<td><strong>Total cholesterol (mmol/l)</strong></td>
<td>3.639 (0.5658)</td>
<td>3.653 (0.7389)</td>
<td>3.646 (0.6513)</td>
<td>0.9499</td>
</tr>
<tr>
<td><strong>β-2 microglobulin</strong></td>
<td>22.64 (6.939)</td>
<td>24.93 (7.225)</td>
<td>23.78 (7.011)</td>
<td>0.4570</td>
</tr>
<tr>
<td><strong>FRAP assay</strong>*</td>
<td>1467 (236.6)</td>
<td>1453 (216.3)</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td><strong>Plasma folate (ng/ml)</strong></td>
<td>5.55 (4.42)</td>
<td>6.29 (2.82)</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td><strong>Whole blood folate (ng/ml)</strong></td>
<td>17.05 (11.71)</td>
<td>19.09 (11.76)</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>

*Student’s t-test*

**employing Welch’s correction**

***Ferric Reducing Ability of Plasma***
LEGENDS FOR FIGURES

Figure 1: Baseline Superoxide Dismutase Levels

Figure 2: Change in Superoxide Dismutase in Control (p = 0.0443) and Active (p = 0.3083) Groups (Student’s t-test).

Figure 3: Baseline Glutathione Peroxidase Levels

Figure 4: Change in Glutathione Peroxidase levels in Control (p = 0.1546) and Active (p = 0.0123) Groups (Student’s t-test).
Figure 3

The figure illustrates the distribution of GPx (iu/gHb) for three categories: GPx Active Baseline, GPx Control Baseline, and GpX all Baseline. The data points are represented by different markers for each category.

Click here to download high resolution image
Figure 4

[Graph showing data points for Control Baseline, Control 6/12, Active Baseline, Active 6/12 plotted against GPx (iu/gHb)]
Dear Dr Mallamaci,

I hope you might be able to consider the attached electronic script entitled “Micronutrient supplementation in maintenance haemodialysis patients enhances activity of antioxidant enzymes” as a candidate for publication in *J Nephrol*.

As a previous invited contributor to *JN* I have formed a high regard for the quality and impact of the journal and believe that it would be an ideal forum for publication of this original and carefully conducted RCT. The strongly significant results of the trial will contribute to the growing picture of amelioration of oxidative stress in haemodialysis patients.

PJG collaborated in the conception and design of the study, supervised the clinical aspects of the project, analysed the data, prepared the draft manuscript and approved the final version.

MHF collaborated in the conception and design of the study, supervised the analytical aspects of the project, reviewed and contributed to revision of the manuscript and approved the final version.

TAM recruited the subjects, was responsible for the direct conduct of the study, reviewed and contributed to revision of the manuscript and approved the final version.

The study was performed in accordance with full ethical approval by ORECNI (the Office for Research Ethics Committees of Northern Ireland) and the
Research Governance Committee of the Western Health and Social Care Trust.

We can confirm that the results presented in this paper have not been published previously in whole or part, except in abstract form.

Yours sincerely,

Dr Peter Garrett
Dr Mary Hannon-Fletcher
Ms Twyla Moffitt.